Michielin, Olivier
Atkins, Michael B https://orcid.org/0000-0003-3901-9924
Koon, Henry B
Dummer, Reinhard
Ascierto, Paolo Antonio https://orcid.org/0000-0002-8322-475X
Clinical trials referenced in this document:
Documents that mention this clinical trial
528 A novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution identified predictive spatial biomarkers in immunotherapy- and targeted therapy-treated melanoma patients
https://doi.org/10.1136/jitc-2025-sitc2025.0528
117 Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for spatial biomarker identification on immunotherapy-treated melanoma patients
https://doi.org/10.1136/jitc-2024-sitc2024.0117
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
https://doi.org/10.1200/jco.21.02961
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
https://doi.org/10.1136/jitc-2021-002995
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
Documents that mention this clinical trial
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
https://doi.org/10.1136/jitc-2021-002995
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)
https://doi.org/10.1016/j.ijrobp.2016.01.038
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
https://doi.org/10.1016/j.ejca.2016.04.005
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
https://doi.org/10.1200/jco.22.01763
Documents that mention this clinical trial
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced <i>BRAF</i>-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).
https://doi.org/10.1200/jco.2024.42.17_suppl.lba9503
Documents that mention this clinical trial
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
Documents that mention this clinical trial
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Documents that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of
<i>BRAF</i>
-mutant advanced melanoma: A matching-adjusted indirect comparison
https://doi.org/10.1136/bmjonc-2025-000912
Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
https://doi.org/10.1136/annrheumdis-2018-213682
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0307
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0301
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations
https://doi.org/10.1136/jmedgenet-2018-105610
Documents that mention this clinical trial
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
https://doi.org/10.1136/jitc-2023-006821
Documents that mention this clinical trial
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Documents that mention this clinical trial
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant,
<i>EGFR</i>
-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9000
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Documents that mention this clinical trial
Commentary on oncolytic viruses: past, present, and future
https://doi.org/10.1136/jitc-2023-007905
429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma
https://doi.org/10.1136/jitc-2020-sitc2020.0429
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
https://doi.org/10.1136/jitc-2020-001621
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
https://doi.org/10.1200/jco.22.00343
OncoVEX<sup>mGM-CSF</sup>expands tumor antigen-specific CD8+ T-cell response in preclinical models
https://doi.org/10.1136/jitc-2022-006374
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling
https://doi.org/10.1136/jitc-2024-009443
Efficacy of immune checkpoint inhibitors for in-transit melanoma
https://doi.org/10.1136/jitc-2019-000440
Documents that mention this clinical trial
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
https://doi.org/10.1136/jitc-2025-012747
606 Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology
https://doi.org/10.1136/jitc-2022-sitc2022.0606
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.
https://doi.org/10.1200/jco.2024.42.16_suppl.9524
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of
<i>BRAF</i>
-mutant advanced melanoma: A matching-adjusted indirect comparison
https://doi.org/10.1136/bmjonc-2025-000912
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Gene of the month: lymphocyte-activation gene 3 (LAG-3)
https://doi.org/10.1136/jclinpath-2021-207517
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
https://doi.org/10.1200/jco.24.01124
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
https://doi.org/10.1200/jco.2023.41.16_suppl.9502
Development of a LAG-3 immunohistochemistry assay for melanoma
https://doi.org/10.1136/jclinpath-2022-208254
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RT
https://doi.org/10.1136/jitc-2021-004218
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2025-012885
1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial
https://doi.org/10.1136/jitc-2022-sitc2022.1473
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8<sup>+</sup> T cell responses capable of curing multi-focal cancer
https://doi.org/10.1136/jitc-2019-000464
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
https://doi.org/10.1200/jco.23.00172
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
https://doi.org/10.1136/jitc-2020-sitc2020.0420
Documents that mention this clinical trial
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Documents that mention this clinical trial
528 A novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution identified predictive spatial biomarkers in immunotherapy- and targeted therapy-treated melanoma patients
https://doi.org/10.1136/jitc-2025-sitc2025.0528
117 Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for spatial biomarker identification on immunotherapy-treated melanoma patients
https://doi.org/10.1136/jitc-2024-sitc2024.0117
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
https://doi.org/10.1200/jco.21.02961
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
https://doi.org/10.1136/jitc-2021-002995
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
Documents that mention this clinical trial
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
https://doi.org/10.1136/jitc-2021-002995
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)
https://doi.org/10.1016/j.ijrobp.2016.01.038
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
https://doi.org/10.1016/j.ejca.2016.04.005
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
https://doi.org/10.1200/jco.22.01763
Documents that mention this clinical trial
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced <i>BRAF</i>-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).
https://doi.org/10.1200/jco.2024.42.17_suppl.lba9503
Documents that mention this clinical trial
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
https://doi.org/10.1136/jitc-2020-001806
Documents that mention this clinical trial
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
https://doi.org/10.1136/jitc-2023-006821
Documents that mention this clinical trial
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant,
<i>EGFR</i>
-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9000
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Documents that mention this clinical trial
Commentary on oncolytic viruses: past, present, and future
https://doi.org/10.1136/jitc-2023-007905
429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma
https://doi.org/10.1136/jitc-2020-sitc2020.0429
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
https://doi.org/10.1136/jitc-2020-001621
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
https://doi.org/10.1200/jco.22.00343
OncoVEX<sup>mGM-CSF</sup>expands tumor antigen-specific CD8+ T-cell response in preclinical models
https://doi.org/10.1136/jitc-2022-006374
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling
https://doi.org/10.1136/jitc-2024-009443
Efficacy of immune checkpoint inhibitors for in-transit melanoma
https://doi.org/10.1136/jitc-2019-000440
Documents that mention this clinical trial
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
https://doi.org/10.1136/jitc-2025-012747
606 Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology
https://doi.org/10.1136/jitc-2022-sitc2022.0606
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.
https://doi.org/10.1200/jco.2024.42.16_suppl.9524
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of
<i>BRAF</i>
-mutant advanced melanoma: A matching-adjusted indirect comparison
https://doi.org/10.1136/bmjonc-2025-000912
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Gene of the month: lymphocyte-activation gene 3 (LAG-3)
https://doi.org/10.1136/jclinpath-2021-207517
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
https://doi.org/10.1200/jco.24.01124
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
https://doi.org/10.1200/jco.2023.41.16_suppl.9502
Development of a LAG-3 immunohistochemistry assay for melanoma
https://doi.org/10.1136/jclinpath-2022-208254
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RT
https://doi.org/10.1136/jitc-2021-004218
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2025-012885
1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial
https://doi.org/10.1136/jitc-2022-sitc2022.1473
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8<sup>+</sup> T cell responses capable of curing multi-focal cancer
https://doi.org/10.1136/jitc-2019-000464
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
https://doi.org/10.1200/jco.23.00172
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
https://doi.org/10.1136/jitc-2020-sitc2020.0420
Documents that mention this clinical trial
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Funding for this research was provided by:
Bristol-Myers Squibb